RISUG: an intravasal injectable male contraceptive
- PMID: 25673546
- PMCID: PMC4345756
RISUG: an intravasal injectable male contraceptive
Abstract
Over the last two decades RISUG has been drawing attention in the field of male contraception. It promises to sterile men for a period of up to 10-15 years. According to recent studies in animal models, it proves to be completely reversible. Practically, there are no better options available that can assure complete sterility and precise reversibility. Regardless of so much of information available, RISUG is still holding up for many reasons, firstly, the available information engender bewilderment such as what is this copolymer, how does it work and is reversal really possible? Secondly, advancement of this outstanding invention is drastically slow and thirdly, effects of long-term contraception with RISUG and reports on evaluation of anomalies (if any) in F 1 , F 2 progenies, are lacking. In this review the lacunae as well as advances in the development of RISUG in the light of published work and available resources are pointed out. Formulation of the RISUG, its mode of action and clinical trials have been addressed with particular emphasis.
Figures
Similar articles
-
Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception.Andrology. 2016 Mar;4(2):306-13. doi: 10.1111/andr.12155. Epub 2016 Jan 8. Andrology. 2016. PMID: 26748683
-
RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.Med Hypotheses. 2005;65(1):61-4. doi: 10.1016/j.mehy.2004.12.030. Med Hypotheses. 2005. PMID: 15893119
-
Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.Indian J Med Res. 2019 Jul;150(1):81-86. doi: 10.4103/ijmr.IJMR_635_18. Indian J Med Res. 2019. PMID: 31571633 Free PMC article. Clinical Trial.
-
Perspectives of contraceptive choices for men.Indian J Exp Biol. 2005 Nov;43(11):1042-7. Indian J Exp Biol. 2005. PMID: 16313067 Review.
-
Vas deferens, a site of male contraception: an overview.Asian J Androl. 2001 Jun;3(2):87-95. Asian J Androl. 2001. PMID: 11404791 Review.
Cited by
-
Studies on biochemical, oxidative and genotoxicity alterations following vas blockage with reversible inhibition of sperm under guidance and reversal in rats.Indian J Pharmacol. 2022 Jan-Feb;54(1):33-40. doi: 10.4103/ijp.IJP_557_20. Indian J Pharmacol. 2022. PMID: 35343205 Free PMC article.
-
Alarming Rise in Global Rabies Cases Calls for Urgent Attention: Current Vaccination Status and Suggested Key Countermeasures.Cureus. 2023 Dec 13;15(12):e50424. doi: 10.7759/cureus.50424. eCollection 2023 Dec. Cureus. 2023. PMID: 38222131 Free PMC article.
-
Sperm impairing microbial factor: potential candidate for male contraception.Reprod Biol Endocrinol. 2020 Sep 30;18(1):96. doi: 10.1186/s12958-020-00654-4. Reprod Biol Endocrinol. 2020. PMID: 32998760 Free PMC article.
-
Current and future contraceptive options for women living with HIV.Expert Opin Pharmacother. 2018 Jan;19(1):1-12. doi: 10.1080/14656566.2017.1378345. Epub 2017 Sep 19. Expert Opin Pharmacother. 2018. PMID: 28891343 Free PMC article. Review.
-
Antifertility effect of methanolic extract of Butea monosperma (Lam.) Taub. flower in male albino rats.Ayu. 2021 Jan-Mar;42(1):57-66. doi: 10.4103/ayu.AYU_91_20. Epub 2022 Dec 7. Ayu. 2021. PMID: 36743278 Free PMC article.
References
-
- Misro MM, Guha SK, Singh H, Mahajan S, Ray AR, Vasudevan P. Injectable non-occlusive chemical contraception in the male-I. Contraception. 1979;20:467–73. - PubMed
-
- Verma K, Misro MM, Singh H, Mahajan S, Ray AR, Guha SK. Histology of the rat vas deferens after injection of a non-occlusive chemical contraceptive. J Reprod Fertil. 1981;63:539–42. - PubMed
-
- Sethi N, Srivastava RK, Singh RK, Bhatia GS, Sinha N. Chronic toxicity of styrene maleic anhydride, a male contraceptive, in rhesus monkeys (Macaca mulatta) Contraception. 1990;42:337–47. - PubMed
-
- Sethi N, Srivastava RK, Singh RK. Histological changes in the vas deferens of rats after injection of a new male antifertility agent ‘SMA’ and its reversibility. Contraception. 1990;41:333–9. - PubMed
-
- Lohiya NK, Suthar R, Khandelwal A, Goyal S, Ansari AS, Manivannan B. Sperm characteristics and teratology in rats following vas occlusion with RISUG ® and its reversal. Int J Androl. 2010;33:e198–206. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical